These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20859991)

  • 21. Genistein suppressed epithelial-mesenchymal transition and migration efficacies of BG-1 ovarian cancer cells activated by estrogenic chemicals via estrogen receptor pathway and downregulation of TGF-β signaling pathway.
    Kim YS; Choi KC; Hwang KA
    Phytomedicine; 2015 Oct; 22(11):993-9. PubMed ID: 26407941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-4 activates androgen receptor through CBP/p300.
    Lee SO; Chun JY; Nadiminty N; Lou W; Feng S; Gao AC
    Prostate; 2009 Feb; 69(2):126-32. PubMed ID: 18819102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opposite effects of CBP and p300 in glucocorticoid signaling in astrocytes.
    Fonte C; Trousson A; Grenier J; Schumacher M; Massaad C
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):220-7. PubMed ID: 17475479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocrine disrupting chemicals may deregulate DNA repair through estrogen receptor mediated seizing of CBP/p300 acetylase.
    Lakshmanan MD; Shaheer K
    J Endocrinol Invest; 2020 Sep; 43(9):1189-1196. PubMed ID: 32253726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation.
    Lau KM; LaSpina M; Long J; Ho SM
    Cancer Res; 2000 Jun; 60(12):3175-82. PubMed ID: 10866308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-alpha: regulation by phosphorylation sites in the A/B region depends on other receptor domains.
    Dutertre M; Smith CL
    Mol Endocrinol; 2003 Jul; 17(7):1296-314. PubMed ID: 12714702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nuclear receptor coactivators function in estrogen receptor- and progestin receptor-dependent aspects of sexual behavior in female rats.
    Molenda-Figueira HA; Williams CA; Griffin AL; Rutledge EM; Blaustein JD; Tetel MJ
    Horm Behav; 2006 Sep; 50(3):383-92. PubMed ID: 16769066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pure estrogen receptor antagonist ICI 182,780 promotes a novel interaction of estrogen receptor-alpha with the 3',5'-cyclic adenosine monophosphate response element-binding protein-binding protein/p300 coactivators.
    Jaber BM; Gao T; Huang L; Karmakar S; Smith CL
    Mol Endocrinol; 2006 Nov; 20(11):2695-710. PubMed ID: 16840538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1), paired-like homeoprotein, through acetylation of the conserved lysine residue adjacent to the homeodomain.
    Iioka T; Furukawa K; Yamaguchi A; Shindo H; Yamashita S; Tsukazaki T
    J Bone Miner Res; 2003 Aug; 18(8):1419-29. PubMed ID: 12929931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.
    Chen M; Ni J; Chang HC; Lin CY; Muyan M; Yeh S
    Carcinogenesis; 2009 May; 30(5):841-50. PubMed ID: 19126643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of the estrogen receptor beta in genistein-induced expression of p21(waf1/cip1) in PC-3 prostate cancer cells.
    Matsumura K; Tanaka T; Kawashima H; Nakatani T
    Anticancer Res; 2008; 28(2A):709-14. PubMed ID: 18507011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding and modulation of p53 by p300/CBP coactivators.
    Lill NL; Grossman SR; Ginsberg D; DeCaprio J; Livingston DM
    Nature; 1997 Jun; 387(6635):823-7. PubMed ID: 9194565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction and functional cooperation between the LIM protein FHL2, CBP/p300, and beta-catenin.
    Labalette C; Renard CA; Neuveut C; Buendia MA; Wei Y
    Mol Cell Biol; 2004 Dec; 24(24):10689-702. PubMed ID: 15572674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
    Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
    Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.
    Lopez GN; Webb P; Shinsako JH; Baxter JD; Greene GL; Kushner PJ
    Mol Endocrinol; 1999 Jun; 13(6):897-909. PubMed ID: 10379889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
    Gougelet A; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic changes in the expression of steroid receptor coactivators and corepressors in the normal human endometrium.
    Shiozawa T; Shih HC; Miyamoto T; Feng YZ; Uchikawa J; Itoh K; Konishi I
    J Clin Endocrinol Metab; 2003 Feb; 88(2):871-8. PubMed ID: 12574227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers.
    Waddell AR; Huang H; Liao D
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34201346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Global transcriptional coactivators CREB-binding protein and p300 are highly essential collectively but not individually in peripheral B cells.
    Xu W; Fukuyama T; Ney PA; Wang D; Rehg J; Boyd K; van Deursen JM; Brindle PK
    Blood; 2006 Jun; 107(11):4407-16. PubMed ID: 16424387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
    Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
    J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.